A phase I clinical trial to evaluate the safety and immunogenicity of a booster dose of a recombinant multiclade HIV-1 adenoviral vector vaccine, VRC-HIVADV014-00-VP, in uninfected subjects who were previously immunized with VRC-HIVDNA016-00-VP in VRC 007
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs VRC-HIVADV014-00-VP (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 16 Jan 2008 Status changed from in progress to completed.
- 22 Oct 2005 New trial record.